Bedaquiline

證據等級: L5

預測適應症: 10 個

Bedaquiline: From MDR Tuberculosis to Bovine Tuberculosis

One-Sentence Summary

Bedaquiline is a first-in-class diarylquinoline antibiotic approved internationally for multidrug-resistant tuberculosis (MDR-TB) treatment, working by selectively inhibiting the mycobacterial F₀F₁-ATP synthase. The TxGNN model predicts it may be effective for Bovine Tuberculosis (Mycobacterium bovis infection) with a score of 99.96%, supported by 0 clinical trials and 3 in vitro publications for this specific indication. Notably, the second-ranked prediction—Inactive (Latent) Tuberculosis—carries significantly stronger clinical evidence (3 clinical trials including one Phase 2/3 trial, 20 publications, Evidence Level L2) and represents the more immediately actionable repurposing opportunity identified in this analysis.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines (internationally approved for MDR-TB treatment)
Predicted New Indication	Tuberculosis, Bovine (M. bovis infection)
TxGNN Prediction Score	99.96%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Bedaquiline (also known as TMC207 or R207910) is the first genuinely novel anti-tuberculosis antibiotic mechanism introduced in over 40 years. Based on in vitro selectivity studies (PMID 19075053), its mechanism centers on highly selective inhibition of the F₀F₁-ATP synthase c subunit in mycobacteria. The same study demonstrated that human mitochondrial ATP synthase shows more than 20,000-fold lower sensitivity to bedaquiline than mycobacterial ATP synthase—explaining both its potent bactericidal activity and its relative tolerability in humans. Critically, bedaquiline retains activity against non-replicating (dormant) mycobacteria, because ATP synthase remains essential for energy maintenance even in metabolically quiescent bacteria; this property is mechanistically relevant to both latent and drug-resistant TB contexts.

Mycobacterium bovis, the causative agent of bovine tuberculosis, belongs to the Mycobacterium tuberculosis complex (MTBC). Within MTBC, the F₀F₁-ATP synthase c subunit—bedaquiline’s primary binding site—is highly conserved at the amino acid sequence level. This structural conservation provides the core mechanistic justification for the TxGNN prediction: activity against M. tuberculosis theoretically extrapolates to M. bovis. Standardized MIC determination methodology for bedaquiline against M. tuberculosis H37Rv has been characterized (PMID 27210281), and assay techniques to prevent drug carryover artifacts have been validated (PMID 18480227)—both essential methodological prerequisites for extending susceptibility testing to M. bovis.

There are, however, important caveats. All three supporting publications tested bedaquiline against M. tuberculosis only; none directly characterized its activity against M. bovis. Moreover, bovine tuberculosis is primarily a veterinary disease and a zoonotic public health concern, not a standard human therapeutic target. The regulatory, logistical, and clinical frameworks for treating M. bovis infection in animals or at-risk humans differ substantially from those governing human MDR-TB treatment. The high TxGNN score most likely reflects MTBC family-level clustering in the knowledge graph rather than direct empirical evidence for this specific indication.

Clinical Trial Evidence

Currently no related clinical trials registered for Tuberculosis, Bovine.

Literature Evidence

(Evidence for primary prediction: Tuberculosis, Bovine)

PMID	Year	Type	Journal	Key Findings
27210281	2016	In vitro / Methodological	Médecine et Maladies Infectieuses	Characterized the impact of different in vitro culture conditions (medium, inoculum, incubation time) on bedaquiline MIC against M. tuberculosis H37Rv; essential methodology for extending susceptibility testing to MTBC members including M. bovis
19075053	2009	In vitro / Basic Science	Antimicrobial Agents and Chemotherapy	Demonstrated >20,000-fold selectivity of bedaquiline (TMC207) for mycobacterial ATP synthase over human mitochondrial ATP synthase; also showed low sensitivity in bovine heart mitochondria, confirming selectivity for the mycobacterial target and establishing the mechanistic foundation for MTBC-wide coverage
18480227	2008	In vitro / Methodological	Journal of Clinical Microbiology	Validated BSA-supplemented media to prevent bedaquiline drug carryover in ex vivo bacterial titrations from mouse organs and patient sputa; critical methodological control for in vivo and clinical susceptibility studies

Philippines Market Information

Bedaquiline is not currently registered in the Philippines. There are no product authorizations recorded in the local regulatory database.

For reference, bedaquiline (brand name Sirturo®) has received regulatory approval in several major jurisdictions:

Jurisdiction	Approval Year	Approved Indication
US FDA	2012 (adults); extended to pediatric use	MDR-TB, as part of combination therapy
EMA	2014	MDR-TB, as part of combination therapy
WHO Essential Medicines	2019 (added); 2022 (guidance updated)	All forms of RR/MDR-TB

A regulatory application, special access scheme, or compassionate use program would be required before any clinical use in the Philippines.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Blocking Data Gap (DG001): Philippines-specific prescribing information has not yet been retrieved. This gap prevents formal safety evaluation and must be resolved before clinical feasibility assessment can proceed. The recommended remediation is to download and parse the originator package insert PDF from the relevant regulatory agency (e.g., FDA Philippines or the US Sirturo® label as a reference standard).

Conclusion and Next Steps

Rank 1 — Tuberculosis, Bovine

Decision: Research Question

Rationale: The mechanistic link is scientifically plausible: bedaquiline’s target (F₀F₁-ATP synthase c subunit) is conserved across all MTBC members including M. bovis. However, no clinical trials exist for this specific indication, all available evidence is in vitro and methodological (not direct M. bovis testing), and the primary disease context is veterinary/zoonotic rather than standard human therapeutics.

To proceed, the following is needed:

Direct in vitro susceptibility testing of bedaquiline against M. bovis reference strains using standardized MIC methodology
Assessment of the zoonotic TB clinical context to determine whether human treatment scenarios warrant further investigation
Collaboration with veterinary infectious disease specialists and public health authorities on the zoonotic TB management framework

Rank 2 — Inactive (Latent) Tuberculosis — Highest Priority Actionable Finding

Decision: Proceed with Guardrails

Rationale: The BREACH-TB trial (NCT06568484, seamless Phase 2/3, n=2,530) is directly testing a 4-week bedaquiline regimen versus standard regimens for TB preventive therapy in people living with HIV and high-risk close contacts of DS/RR-TB patients. Bedaquiline’s unique activity against dormant mycobacteria, supported by a mouse model of TB preventive therapy (PMID 34939891) and multiple mechanistic reviews, provides strong biological rationale. This is the most actionable repurposing direction in this analysis.